PD L1 News and Research

RSS

Oncologists respond quickly to emerging FDA safety data for drugs, study finds

Within six months of the U.S. Food and Drug Administration's move to restrict the label of two immunotherapies, usage of those therapies among oncologists dropped by about 50 percent, according to a new study from researchers in the Abramson Cancer Center at the University of Pennsylvania.

24 Sep 2019

Pembrolizumab provides added benefit for subpopulations of patients with metastatic NSCLC

In early July, the German Institute for Quality and Efficiency in Health Care conducted two early benefit assessments to investigate whether certain drug combinations with pembrolizumab have advantages in comparison with the respective appropriate comparator therapy for patients with metastatic squamous or non-squamous non-small cell lung cancer.

20 Sep 2019

Mutations linked with sensitivity or resistance to immunotherapy in mNSCLC

The relationship between gene alterations and response to anti-PD-L1 with and without anti-CTLA-4 are not well characterized.

10 Sep 2019

Age affects efficacy of immunotherapy treatment for breast cancer, preclinical study reveals

Recent clinical trials have indicated that immune checkpoint blockade (ICB) therapy, which is designed to unleash a patient's immune system to attack cancer, has been revolutionary in its implications for breast cancer treatment, especially for its potential to treat patients with triple negative breast cancer.

8 Sep 2019

Genetically altering protein in colon cancer cells may enhance efficacy of chemotherapy

Colorectal cancer outcomes may improve by genetically altering an immune-regulatory protein in cancer cells, making the cells more vulnerable to chemotherapy. That's according to new Mayo Clinic research.

27 Aug 2019

Researchers develop new gene editing system that could be used for anticancer immunotherapy

Dr. Mihue Jang and her group at the Center for Theragnosis of the Korea Institute of Science and Technology announced that they have developed a new gene-editing system that could be used for anticancer immunotherapy through the simultaneous suppression of proteins that interfere with the immune system expressed on the surface of lymphoma cells and activation of cytotoxic T lymphocyte, based on the results of joint research conducted with Prof. Seokmann Hong and his group at Sejong University.

20 Aug 2019

Study shows how cigarette smoke drives tumor aggressiveness in head and neck cancer

Head and neck cancer is the sixth most common cancer in the world. The vast majority of cases are head and neck squamous cell carcinoma, a type of cancer that arises in the outer layer of the skin and mucous membranes of the mouth, nose and throat.

8 Aug 2019

Research offers molecular details of pancreatic cancer's ability to invade and evade

Two known gene mutations induce pathways that enhance pancreatic cancer's ability to invade tissues and evade the immune system.

6 Aug 2019

Scientists use AI to recognize patterns in breast cancer

Scientists have used artificial intelligence to recognize patterns in breast cancer - and uncovered five new types of the disease each matched to different personalized treatments.

2 Aug 2019

New drug combination successfully reduces levels of bovine leukemia virus

Scientists have succeeded in reducing levels of the bovine leukemia virus in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.

2 Aug 2019

Scientists discover novel mechanism of action for NK cells in checkpoint inhibitor for cancer

PD-L1 checkpoint inhibitors are a powerful and growing form of immunotherapy used to treat melanoma, kidney cancer, head and neck cancers, Hodgkin's lymphoma and other cancers.

27 Jul 2019

Novel biomarker-guided approach has potential for treatment of common liver cancer

A study at The University of Texas MD Anderson Cancer Center discovered a cellular pathway tied to cancer that may be beneficial in reducing side effects and extending duration of immunotherapy in some patients with hepatocellular carcinoma, the most common form of liver cancer.

16 Jul 2019

Non-classical monocytes directly involved in regulation of immune response

Non-classical monocytes were long thought to play a purely surveillance role in the immune system. With the aid of a novel marker, Ludwig-Maximilians-Universitaet in Munich researchers have now shown that they are directly involved in the regulation of immune response

24 Jun 2019

Researchers provide insight into unintended consequence of immune checkpoint inhibitors

Immune checkpoint inhibitors are an emerging type of cancer immunotherapy that uses the immune system to attack cancer cells.

12 Jun 2019

Researchers develop novel imaging test to predict immunotherapy response in kidney cancer

A novel imaging test shows promise for identifying kidney cancer patients most likely to benefit from immunotherapy.

4 Jun 2019

Combination immunotherapy shows promise in pre-surgical setting for early-stage lung cancers

Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response rate of 33 percent of treated patients with early-stage, resectable non-small cell lung cancers, meaning these patients had less than or equal to 10 percent viable tumor remaining at surgery.

3 Jun 2019

Immunotherapy increases five-year survival rate of patients with advanced non-small cell lung cancer

In a study led by UCLA investigators, treatment with the immunotherapy drug pembrolizumab helped more than 15% of people with advanced non-small cell lung cancer live for at least five years - and 25% of patients whose tumor cells had a specific protein lived at least that long.

3 Jun 2019

Pre-surgical neoadjuvant treatment shows promise in trial for patients with operable NSCLC

For patients with operable non-small cell lung cancer, pre-surgical "neoadjuvant" treatment with an immune checkpoint inhibitor was well tolerated and, in many cases, caused significant tumor cell death in a large, multicenter clinical trial involving investigators at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and nine other research centers

31 May 2019

FDA approves new treatment for adults with metastatic bladder cancer

The U.S. Food and Drug Administration today granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy.

12 Apr 2019

Unusually small antibodies could help CAR T-cell therapies to kill solid tumors

In 1989, two undergraduate students at the Free University of Brussels were asked to test frozen blood serum from camels, and stumbled on a previously unknown kind of antibody. I